Debra C. Stuurman

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Design, Synthesis, and Preclinical Evaluation of Novel Dimeric RM2-Based Radioligands for GRPR-Targeted Breast Cancer Imaging.

Design, Synthesis, and Preclinical Evaluation of Novel Dimeric RM2-Based Radioligands for GRPR-Targeted Breast Cancer Imaging.

Journal: Molecular pharmaceutics

Published: July 21, 2026

Novel dual-targeted gastrin-releasing peptide receptor and fibroblast activation protein radiopharmaceuticals for molecular imaging of heterogeneous breast tumors.

Novel dual-targeted gastrin-releasing peptide receptor and fibroblast activation protein radiopharmaceuticals for molecular imaging of heterogeneous breast tumors.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: June 16, 2026

A new series of FAP inhibitors for cancer imaging based on 8-substituted (4-quinolinoyl)-glycyl-2-cyanopyrrolidine.

A new series of FAP inhibitors for cancer imaging based on 8-substituted (4-quinolinoyl)-glycyl-2-cyanopyrrolidine.

Journal: Nuclear medicine and biology

Published: April 01, 2026

Head-to-head comparison of [177Lu]Lu-FAP-2286 and [161Tb]Tb-FAP-2286 efficacy in a PDAC mouse model.

Head-to-head comparison of [177Lu]Lu-FAP-2286 and [161Tb]Tb-FAP-2286 efficacy in a PDAC mouse model.

Journal: EJNMMI research

Published: December 01, 2025

Assessment of quality control and effect of radiolysis on the in vivo biodistribution of [177Lu]Lu-PSMA-I&T.

Assessment of quality control and effect of radiolysis on the in vivo biodistribution of [177Lu]Lu-PSMA-I&T.

Journal: EJNMMI radiopharmacy and chemistry

Published: October 03, 2025

Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals.

Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals.

Journal: EJNMMI radiopharmacy and chemistry

Published: June 17, 2025

Chemotherapy alters radiosensitivity and GRPR expression of prostate and breast cancer cells.

Chemotherapy alters radiosensitivity and GRPR expression of prostate and breast cancer cells.

Journal: EJNMMI research

Published: February 19, 2025

eSOMA-DM1, a Maytansinoid-Based Theranostic Small-Molecule Drug Conjugate for Neuroendocrine Tumors.

eSOMA-DM1, a Maytansinoid-Based Theranostic Small-Molecule Drug Conjugate for Neuroendocrine Tumors.

Journal: Bioconjugate chemistry

Published: October 12, 2024

In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide theranostics and other oncological interventions.

In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide theranostics and other oncological interventions.

Journal: EJNMMI radiopharmacy and chemistry

Published: June 12, 2024

eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors.

eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors.

Journal: EJNMMI radiopharmacy and chemistry

Published: April 08, 2024

Rapid Assessment of Bio-distribution and Antitumor Activity of the Photosensitizer Bremachlorin in a Murine PDAC Model: Detection of PDT-induced Tumor Necrosis by IRDye® 800CW Carboxylate, Using Whole-Body Fluorescent Imaging.

Rapid Assessment of Bio-distribution and Antitumor Activity of the Photosensitizer Bremachlorin in a Murine PDAC Model: Detection of PDT-induced Tumor Necrosis by IRDye® 800CW Carboxylate, Using Whole-Body Fluorescent Imaging.

Journal: Molecular imaging and biology

Published: January 29, 2024

Darolutamide does not interfere with OATP-mediated uptake of docetaxel.

Darolutamide does not interfere with OATP-mediated uptake of docetaxel.

Journal: International journal of cancer

Published: November 15, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026